Pre-made Mipasetamab benchmark antibody ( Whole mAb, anti-AXL therapeutic antibody, Anti-ARK/UFO/JTK11/Tyro7 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Mipasetamab biosimilar, Whole mAb, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mipasetamab Uzoptirine or ADCT-601 ia humanized antibody that binds to human AXL conjugated using Glycoconnect? technology to a linker with a PBD-dimer toxin. Once bound to an AXL-expressing cell, ADCT-601 is internalized into the cell, where enzymes release the PBD-based payload.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-345-1mg	1mg	3090
GMP-Bios-ab-345-10mg	10mg	Inquiry
GMP-Bios-ab-345-100mg	100mg	Inquiry
GMP-Bios-ab-345-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Mipasetamab biosimilar, Whole mAb, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody
INN Name	Mipasetamab
Target	AXL
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	2021
Companies	ADC Therapeutics
Conditions Approved	na
Conditions Active	Solid tumours;Advanced or metastatic solid tumours
Conditions Discontinued	na
Development Tech	na